REFERENCES:
1) Linguela E et al (1993) FEBS Lett. 318:95-99; Canessa CM et al (1993) Nature
361:467-470; Snyder PM et al (1994) J. Biol. Chem. 269:24379-83; Waldmann R et al
(1995) J. Biol. Chem
Analysis (2
nd
ed.), Volume II (Hans-Ulrich
Bergmeyer, ed.), Academic Press, Inc. (New York,
NY), pp. 860-864 (1974).
2. Mössner, E., et al., Hoppe-Seyler’s Z. Physiol.
Chem., 361, 543-549 (
ed.). Academic Press,
Inc. (New York, NY), pp. 860-864 (1974).
2. Mössner, E. et al., Hoppe-Seyler's Z. Physiol.
Chem., 361(4), 543-549 (1980).
3. Ozmadenci, Duygu, "Netrin-1 function in somatic
commercial kits for the determination of novel biomarkers for clinical drug devel-
opment. Bioanalysis, 2, 237–247.
Selby, C. (1999). Interference in immunoassay. Annals of Clinical Biochemistry, 36,
704–721
Kinase 2 (ERK-2) M7431 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
535 p38 MAPK M0800 5594 MAPK1 P NP_002736.3,NP_620407.1 , n/d y y
424 MAP Kinase (ERK-1) M7927 5595 MAPK3 P NP_001035145.1 y y y
247 ERK5
Kinase 2 (ERK-2) M7431 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
535 p38 MAPK M0800 5594 MAPK1 P NP_002736.3,NP_620407.1 , n/d y y
424 MAP Kinase (ERK-1) M7927 5595 MAPK3 P NP_001035145.1 y y y
247 ERK5
Kinase 2 (ERK-2) M7431 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
535 p38 MAPK M0800 5594 MAPK1 P NP_002736.3,NP_620407.1 , n/d y y
424 MAP Kinase (ERK-1) M7927 5595 MAPK3 P NP_001035145.1 y y y
247 ERK5
H9908 M y y n/d
359 phospho-Histone H3 (pSer10) H0412 P y n/d n/d
360 Anti Cy3+Cy5 C0992 M NA NA NA
361 SUV39H1 Histone Methyl Transferase S8316 M y y n/d
362 HMG-1 H9537 M y y y
363 hMps1 M5818 M y n/d
Hist2h3b,Hist1h NP_066298.1,NP_003522.1,NP_835510.1,NP_066403.2,NP_65 P y n/d n/d
360 Anti Cy3+Cy5
361 SUV39H1 Histone Methyl Transferase S8316 20937, 6839 Suv39h1,SUV39H1 NP_035644.1,NP_003164.1 M y y
066298.1,NP_003522.1,NP_835510.1,NP_066403.2,NP_659539.1,NP_4464 P y n/d n/d
360 Anti Cy3+Cy5 C0992
361 SUV39H1 Histone Methyl Transferase S8316 20937, 6839 Suv39h1,SUV39H1 NP_035644.1,NP_003164.1 M y y
endcapped, 2 µm
Mobile phase A: Water
B: Acetonitrile
Gradient 0 min 55% B
0.8 min 55-100% B
0.9-2 min re-equilibration with 55% B
Flow rate 1.1 mL/min
Pressure 505 bar
Detection UV 247 nm
Temperature
endothelial growth factor receptor-2 (VEGFR-2 or KDR/Flk-1) comprising residues
247 - 261. Acts as an inhibitor of VEGF-stimulated autophosphorylation of
VEGFR-2 and inhibits the proliferation and migration